Literature DB >> 12234281

Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions.

Michael Allon1, Michelle L Robbin.   

Abstract

National guidelines promote increasing the prevalence of fistula use among hemodialysis patients. The prevalence of fistulas among hemodialysis patients reflects both national, regional, and local practice differences as well as patient-specific demographic and clinical factors. Increasing fistula prevalence requires increasing fistula placement, improving maturation of new fistulas, and enhancing long-term patency of mature fistulas for dialysis. Whether a patient receives a fistula depends on several factors: timing of referral for dialysis and vascular access, type of fistula placed, patient demographics, preference of the nephrologist, surgeon, and dialysis nurses, and vascular anatomy of the patient. Whether the placed fistula is useable for dialysis depends on additional factors, including adequacy of vessels, surgeon's experience, patient demographics, nursing skills, minimal acceptable dialysis blood flow, and attempts to revise immature fistulas. Whether a mature fistula achieves long-term patency depends on the ability to prevent and correct thrombosis. An optimal outcome is likely when there is (1) a multidisciplinary team approach to vascular access; (2) consensus about the goals among all interested parties (nephrologists, surgeons, radiologists, dialysis nurses, and patients); (3) early referral for placement of vascular access; (4) restriction of vascular access procedures to surgeons with demonstrable interest and experience; (5) routine, preoperative mapping of the patient's arteries and veins; (6) close, ongoing communication among the involved parties; and (7) prospective tracking of outcomes with continuous quality assessment. Implementing these measures is likely to increase the prevalence of fistulas in any given dialysis unit. However, differences among dialysis units are likely to persist because of differences in gender, race, and co-morbidity mix of the patient population.

Entities:  

Mesh:

Year:  2002        PMID: 12234281     DOI: 10.1111/j.1523-1755.2002.kid551.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  166 in total

1.  Two-stage brachial-basilic transposition fistula provides superior patency rates for dialysis access in a safety-net population.

Authors:  Eduardo Gonzalez; Jeffry L Kashuk; Ernest E Moore; Stuart Linas; Angela Sauaia
Journal:  Surgery       Date:  2010-08-19       Impact factor: 3.982

2.  Comparison of radiocephalic fistulas placed in the proximal forearm and in the wrist.

Authors:  Rajeshkumar Bhalodia; Michael Allon; Alan M Hawxby; Ivan D Maya
Journal:  Semin Dial       Date:  2010-08-13       Impact factor: 3.455

3.  We Need to Train the Trainers.

Authors:  Arif Asif; Gerald A Beathard
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

4.  Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor.

Authors:  Sun Hyung Kwon; Li Li; Yuxia He; Chieh Sheng Tey; Huan Li; Ilya Zhuplatov; Seung-Jung Kim; Christi M Terry; Donald K Blumenthal; Yan-Ting Shiu; Alfred K Cheung
Journal:  J Vasc Res       Date:  2016-01-21       Impact factor: 1.934

5.  Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease.

Authors:  Joy P Walker; Jade S Hiramoto; Warren J Gasper; Philip Auyang; Michael S Conte; Joseph H Rapp; David H Lovett; Christopher D Owens
Journal:  J Vasc Surg       Date:  2014-02-28       Impact factor: 4.268

Review 6.  Vascular access for hemodialysis: postoperative evaluation and function monitoring.

Authors:  Konstantinos Leivaditis; Stelios Panagoutsos; Athanasios Roumeliotis; Vassilios Liakopoulos; Vassilis Vargemezis
Journal:  Int Urol Nephrol       Date:  2013-09-18       Impact factor: 2.370

7.  Risk factors associated with inadequate veins for placement of arteriovenous fistulas for hemodialysis.

Authors:  Yuichi Sato; Masahito Miyamoto; Shina Sueki; Tsutomu Sakurada; Kenjiro Kimura; Ryuto Nakazawa; Maki Yoshioka; Hideo Sasaki; Satetsu Miyano; Tatsuya Chikaraishi
Journal:  J Artif Organs       Date:  2013-09-11       Impact factor: 1.731

8.  The mouse aortocaval fistula recapitulates human arteriovenous fistula maturation.

Authors:  Kota Yamamoto; Clinton D Protack; Masayuki Tsuneki; Michael R Hall; Daniel J Wong; Daniel Y Lu; Roland Assi; Willis T Williams; Nirvana Sadaghianloo; Hualong Bai; Tetsuro Miyata; Joseph A Madri; Alan Dardik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

9.  Comorbidities do not influence primary fistula success in incident hemodialysis patients: a prospective study.

Authors:  Wenjie Wang; Brendan Murphy; Serdar Yilmaz; Marcello Tonelli; Jennifer Macrae; Braden J Manns
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-07       Impact factor: 8.237

10.  Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes.

Authors:  Ke Wang; Leila R Zelnick; Peter B Imrey; Ian H deBoer; Jonathan Himmelfarb; Michael D Allon; Alfred K Cheung; Laura M Dember; Prabir Roy-Chaudhury; Miguel A Vazquez; John W Kusek; Harold I Feldman; Gerald J Beck; Bryan Kestenbaum
Journal:  Am J Nephrol       Date:  2018-08-02       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.